{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ef0ad954320b108b12f7e8d/6ae32c1b5a3cc3c4c48ea711?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How can ECP be positioned in the current GvHD treatment landscape as a steroid-free intervention?​​  ","description":"<p>The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How can ECP be positioned in the current GvHD treatment landscape as a steroid-free intervention?​​ </p><p><br></p><p>During this interview, Zeiser discusses the potential positioning of extracorporeal photopheresis (ECP) in the treatment landscape for acute graft-versus-host disease (GvHD) and chronic GvHD, noting that corticosteroids remain the standard first-line treatment in both settings. He highlights the steroid-sparing potential of ECP and considers its role as a second- or later-line treatment option, either alone or in combination with other agents, including ruxolitinib. He also emphasizes the need for further prospective studies to clarify the optimal sequencing of ECP and its use in combination with other therapies. </p><p><br></p><p><em>Intended for healthcare professionals. This educational resource is independently supported by Therakos. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</em> </p>","author_name":"Scientific Education Support"}